For those trying to perpetuate negativity concerning the financial position, this is from the AGM statement :
Looking at the Company's financial position: Sareum ended the fiscal year to 30 June 2021 with a robust cash position having raised £2.37m (before expenses) from two subscriptions by a high-net-worth individual in June 2021. A further £2.18m (before expenses) was raised in July and August 2021 with two further share subscriptions by new high-net-worth individuals plus an exercise of warrants, bringing the total raised to approximately £4.6m to fund the further development of SDC-1801 and SDC-1802. Sareum's cash position as at 30 September 2021 was approximately £4.4m.
Maidit- to quote: "over the years is becoming a joke.. H2 should have been June half, year, and not July or August into Q3 , if it's going to be change to q3 tell us before deadline run out, not after, as the Market is unforgiving when you mess with the expectation,"
You are deliberately misleading the board here. The AGM statement clearly stated" during mis-2022"
" The data from these studies will be crucial to the progression of this CTA, which we remain on track to submit during mid-2022."
Please provide a clear example of where SAR have missed a deadline.
"We are pleased to report that the final toxicology and safety studies required to file for an exploratory Clinical Trial Authorisation ("CTA") have been completed and we expect the finalised reports in the first quarter of 2022. The data from these studies will be crucial to the progression of this CTA, which we remain on track to submit during mid-2022. While data analysis is still in progress, we are confident that the studies have met their objectives of identifying any organs or tissues that might be susceptible to high-dose toxicity and determining the appropriate first-in-human dose. The results received to date fully support our plan to submit this CTA for SDC-1801."
All- it's getting to the point now where the threads are so fragmented that it's hard to follow any discussion, mainly because there are users (not naming names) who are creating new threads when replying to messages.
I would urge everyone to report this behavior as it is ruining the board.
RE: RE: Maidit - stop new threads21 May 2022 22:56
Hi Maidit - I like a lot of your posts and think that your positivity is to be admired, but I think what people are trying to say is that you often create a new thread every time you reply to an existing one. I don't know what you're doing to make this happen but it does unfortunately break the 'flow' of any given discussion and fragments the board, making it harder for everyone to follow what's going on.
As I say please take this as a friendly pointer as I often enjoy reading your posts, but really do wish they were all in the same thread! :)
RNS - European patent granted for 180211 Apr 2022 07:05
Sareum Holdings plc
("Sareum" or the "Company")
European Patent Granted for Sareum's SDC-1802, a Novel Small Molecule TYK2/JAK1 Inhibitor, for the Treatment of T-cell Acute Lymphoblastic Leukaemia
Cambridge, UK, 11 April 2022 - Sareum Holdings plc (AIM: SAR), the specialist drug development company, announces that, further to its announcement on 15 December 2021, the European Patent Office has now issued a formal notification of grant for a patent in respect of an invention associated with Sareum's proprietary SDC-1802 TYK2/JAK1 inhibitor programme. The patent will come into effect on 4 May 2022.
The patent (EPO Patent no. EP3528806) will protect the SDC-1802 molecule and pharmaceutical preparations thereof as a therapeutic to treat T-cell acute lymphoblastic leukaemia (T-ALL - a cancer of a particular type of white blood cell called a T lymphocyte) and other cancers that are dependent on TYK2 kinase for survival. This programme is in preclinical development.
Sareum's CSO, Dr John Reader, commented:
"This newly issued European patent for SDC-1802 expands our already broad and robust patent portfolio covering both our novel TYK2/JAK1 inhibitor candidates and further supports their commercial potential as new treatments for autoimmune diseases and cancer. Building a strong intellectual property portfolio around our TYK2/JAK1 assets is a core strategic focus for Sareum that we believe is creating important value for our shareholders."
What I am finding interesting is that another one of my stocks also got listed on the MSCI index at the same time as Sareum... Exactly the same behaviour SP-wise since then in the run-up to Dec 1st, only there is no PH involvement.
Yes - I was also going to say this marks a change in tactics as one of their fundamental rules has always been to start new threads with negative headlines.
However, they've now twigged (after many years) that by getting Thoth's posts removed they are also cutting off valid counter-arguments to their constant drivel, so we do now need to copy and repaste any hint informative which gets taken down.
Steady... I'm totally with you on that earlier point. I have followed many bbs on LSE and this is by far the best,with potential trolls being weeded out very quickly. There are a large number of very knowledgeable LTHs contributing here and I would hate to see this become fragmented.